Atossa Therapeutics, Inc. (ATOS) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (DMD).
This designation provides important regulatory incentives designed to support the development of therapies for rare diseases. It follows the FDA's earlier decision granting (Z)-endoxifen Rare Pediatric Disease designation, further underscoring the potential of this therapy in addressing unmet medical needs for patients living with DMD.
ATOS closed Friday's regular trading session at $0.6150, up $0.0349 or 6.02% as of 4:00 PM EST. In after-hours trading, the stock advanced further to $0.6948, a gain of $0.08 or 12.98% by 7:59 PM EST.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.